With IPO under its belt, important milestones on the horizon for G1 Therapeutics

After raising more than $108 million in its initial public offering last month, Research Triangle Park-based G1 Therapeutics (Nasdaq: GTHX) is expecting important milestones for its cancer therapy candidates in 2018. Eric Schmidt, a managing director and senior research analyst at Cowen and Company, says that "the real money to be made or lost will be in 2018 [with] the potential for much more proof-of-concept data around trilaciclib and G1T38. ... Both are very high-interest programs for us." For… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

from MedWorm via o.lakala70 on Inoreader http://ift.tt/2ujP4kl
via IFTTT